Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
PFIZER TEVA PHARMA |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
PFIZER Mar-23 |
TEVA PHARMA Dec-13 |
PFIZER/ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 4,662 | 3,486 | - | |
Low | Rs | 3,407 | 3,028 | - | |
Sales per share (Unadj.) | Rs | 530.0 | 2,000.5 | - | |
Earnings per share (Unadj.) | Rs | 136.4 | 125.0 | - | |
Cash flow per share (Unadj.) | Rs | 159.4 | 286.7 | - | |
Dividends per share (Unadj.) | Rs | 70.00 | 109.40 | - | |
Avg Dividend yield | % | 1.7 | 3.4 | 51.7% | |
Book value per share (Unadj.) | Rs | 701.0 | 2,222.2 | - | |
Shares outstanding (eoy) | m | 45.75 | 848.00 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 7.6 | 1.6 | 467.6% | |
Avg P/E ratio | x | 29.6 | 26.1 | 113.5% | |
P/CF ratio (eoy) | x | 25.3 | 11.4 | 222.7% | |
Price / Book Value ratio | x | 5.8 | 1.5 | 392.7% | |
Dividend payout | % | 51.3 | 87.5 | 58.6% | |
Avg Mkt Cap | Rs m | 184,576 | 2,761,843 | 6.7% | |
No. of employees | `000 | NA | 44.9 | 0.0% | |
Total wages/salary | Rs m | 3,317 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 37,744.4 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 2,357.9 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 24,248 | 1,696,422 | 1.4% | |
Other income | Rs m | 1,011 | 0 | - | |
Total revenues | Rs m | 25,258 | 1,696,422 | 1.5% | |
Gross profit | Rs m | 8,420 | 464,566 | 1.8% | |
Depreciation | Rs m | 1,055 | 137,123 | 0.8% | |
Interest | Rs m | 135 | 33,320 | 0.4% | |
Profit before tax | Rs m | 8,240 | 294,122 | 2.8% | |
Minority Interest | Rs m | 0 | 1,336 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -193,075 | -0.0% | |
Tax | Rs m | 2,001 | -3,591 | -55.7% | |
Profit after tax | Rs m | 6,239 | 105,974 | 5.9% | |
Gross profit margin | % | 34.7 | 27.4 | 126.8% | |
Effective tax rate | % | 24.3 | -1.2 | -1,988.8% | |
Net profit margin | % | 25.7 | 6.2 | 411.9% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 24,933 | 1,145,757 | 2.2% | |
Current liabilities | Rs m | 6,574 | 999,197 | 0.7% | |
Net working cap to sales | % | 75.7 | 8.6 | 876.4% | |
Current ratio | x | 3.8 | 1.1 | 330.8% | |
Inventory Days | Days | 93 | 91 | 102.9% | |
Debtors Days | Days | 2 | 96 | 2.4% | |
Net fixed assets | Rs m | 13,780 | 554,089 | 2.5% | |
Share capital | Rs m | 458 | 4,176 | 11.0% | |
Net worth | Rs m | 32,073 | 1,884,403 | 1.7% | |
Long term debt | Rs m | 0 | 867,418 | 0.0% | |
Total assets | Rs m | 39,031 | 3,876,868 | 1.0% | |
Interest coverage | x | 62.1 | 9.8 | 632.2% | |
Debt to equity ratio | x | 0 | 0.5 | 0.0% | |
Sales to assets ratio | x | 0.6 | 0.4 | 142.0% | |
Return on assets | % | 16.3 | 3.6 | 454.5% | |
Return on equity | % | 19.5 | 5.6 | 345.9% | |
Return on capital | % | 26.1 | 4.9 | 529.5% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 3,557 | 270,322 | 1.3% | |
From Investments | Rs m | -361 | -95,786 | 0.4% | |
From Financial Activity | Rs m | -3,458 | -324,269 | 1.1% | |
Net Cashflow | Rs m | -262 | -149,733 | 0.2% |
Compare PFIZER With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US)
Compare PFIZER With: ADESHWAR MEDITEX S.S.ORGANICS PARNAX LAB VAISHALI PHARMA BAFNA PHARMA
It was indeed a volatile trading session for Indian share markets yesterday.